INC.;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE
发明人:
Alejandro V. Villagra,Eduardo M. Sotomayor
申请号：
US16800377
公开号：
US20200188366A1
申请日:
2020.02.25
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a thereapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a thereapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.
